7,107 Matching Annotations
  1. Mar 2020
  2. www.facebook.com www.facebook.com
    A recent paper has shown that novel coronavirus 2019-nCoV uses the SARS-coronavirus receptor ACE2 and the transmembrane protease serine-2 (TMPRSS2) for entering the target cells (https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1?fbclid=IwAR2pEpKv1VN3o2zjUD0RjguQFtspH0nb5qhvYUt3z1evyNwVYFI-A1ylumU). Today we would like to share with you what kind of information is contained on ACE2 in another database, BRENDA™, which we distribute. According to the record in BRENDA™, ACE2 is associated with quite a number of diseases in human, among them heart failure, hypertension, acute lung injury, infections (associated with SARS & influenza). The record mentions about 100 inhibitors; for some even the concentration used in experiment and the amount of inhibition is provided directly. ACE2 exists as membrane-bound and as a soluble form. The latter is generated by cleavage of the membrane-bound form (Brenda ref 707074 =PMID 19411314). In case of the SARS-associated coronavirus (SARS-CoV) the membrane-bound form of ACE2 serves as virus receptor in vitro, and shedding is not required for infection to occur. The transmembrane protease serine-2 (TMPRSS2) has found to activate the spike protein of the SARS-CoV and to positively affect entry of the virus. Many more challenging and thrilling findings will have to be made to completely elucidate all facets of the 2019-nCoV novel coronavirus and its action. We hope very much that powerful information resources, like the databases of our portfolio, will contribute to this fight. #coronavirus #Covid19 #Covid_19 #2019nCoV #BRENDA #geneXplain
    1